JP2016510596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510596A5 JP2016510596A5 JP2015561737A JP2015561737A JP2016510596A5 JP 2016510596 A5 JP2016510596 A5 JP 2016510596A5 JP 2015561737 A JP2015561737 A JP 2015561737A JP 2015561737 A JP2015561737 A JP 2015561737A JP 2016510596 A5 JP2016510596 A5 JP 2016510596A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- acid sequence
- amino acid
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037240 fusion proteins Human genes 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- 102100000643 SMAD7 Human genes 0.000 claims 5
- 108010021883 Smad7 Protein Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000001737 promoting Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 230000003110 anti-inflammatory Effects 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 102100017669 SMAD2 Human genes 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 108010007585 Smad2 Protein Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003172 anti-dna Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000010393 epithelial cell migration Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000010927 mucositis Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000000865 phosphorylative Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 102000015609 tat Gene Products Human genes 0.000 claims 1
- 108010038756 tat Gene Products Proteins 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 200000000019 wound Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (17)
- タンパク質導入ドメインおよびＳｍａｄ７ドメインを含む、医薬として使用するための融合タンパク質であって、前記Ｓｍａｄ７ドメインが
（ｉ）ＳＥＱ ＩＤ ＮＯ：１２に記載のアミノ酸配列のアミノ酸２〜２５８、または位置２１６のＭｅｔがＬｅｕに改変されているその変異体；
（ｉｉ）ＳＥＱ ＩＤ ＮＯ：１２に記載のアミノ酸配列のアミノ酸２０３〜２５８、または位置２１６のＭｅｔがＬｅｕに改変されているその変異体；
（ｉｉｉ）ＳＥＱ ＩＤ ＮＯ：１２に記載のアミノ酸配列のアミノ酸２５９〜４２６；
（ｉｖ）ＳＥＱ ＩＤ ＮＯ：１２に記載のアミノ酸配列のアミノ酸２０３〜２１７、または位置２１６のＭｅｔがＬｅｕに改変されているその変異体；および
（ｖ）位置２１６のＭｅｔがＬｅｕに改変されているＳＥＱ ＩＤ ＮＯ：１２に記載のアミノ酸配列；
からなる群より選択され、
前記Ｓｍａｄ７ドメインが１または複数のＳｍａｄ７の生物学的活性を有する、
融合タンパク質。 - 位置２１６のＭｅｔがＬｅｕに改変されている、請求項１に記載の融合タンパク質。
- タンパク質導入ドメインがＨＩＶ由来のＴａｔタンパク質の変異体である、請求項１に記載の融合タンパク質。
- タンパク質導入ドメインがＳＥＱ ＩＤ ＮＯ：２、ＳＥＱ ＩＤ ＮＯ：４、およびＳＥＱ ＩＤ ＮＯ：６からなる群より選択される、請求項３に記載の融合タンパク質。
- １または複数のエピトープタグまたは精製タグをさらに含む、請求項１〜４のいずれかに記載の融合タンパク質。
- 融合タンパク質のアミノ酸配列がＳＥＱ ＩＤ ＮＯ：２７に示される、請求項１に記載の融合タンパク質。
- １または複数の生物学的活性が細胞遊走の媒介、細胞増殖の増加、放射線誘発ＤＮＡ損傷の減少、および線維化反応の阻害からなる群より選択される、請求項６に記載の融合タンパク質。
- 融合タンパク質のアミノ酸配列がＳＥＱ ＩＤ ＮＯ：２５に示される、請求項１に記載の融合タンパク質。
- １または複数の生物学的活性がＳｍａｄ２のリン酸化の減少または除去、ＮＦ−κＢｐ５０サブユニットの核転座の減少または除去、細胞増殖の増加、上皮細胞遊走の増加、アポトーシスの減少、放射線誘発ＤＮＡ損傷の減少、炎症の減少、および脈管形成の減少からなる群より選択される、請求項８に記載の融合タンパク質。
- 融合タンパク質のアミノ酸配列がＳＥＱ ＩＤ ＮＯ：９８に示される、請求項１に記載の融合タンパク質。
- １または複数の生物学的活性が細胞生存の促進、抗炎症、およびｐＳｍａｄ２の阻害からなる群より選択される、請求項１０に記載の融合タンパク質。
- Ｓｍａｄ７ドメインのアミノ酸配列がＳＥＱ ＩＤ ＮＯ：１２におけるアミノ酸２０３〜２５８として示される、請求項１記載の融合タンパク質。
- １または複数の生物学的活性が細胞増殖の促進、細胞生存の促進、抗炎症、抗ＤＮＡ損傷、およびｐＳｍａｄ２の阻害からなる群より選択される、請求項１２に記載の融合タンパク質。
- 放射線療法または化学療法により誘発される口腔粘膜炎または組織損傷の治療または予防において使用するための、請求項１〜１３のいずれかに記載の融合タンパク質。
- 自己免疫疾患、乾癬、または皮膚炎の治療または予防において使用するための、請求項１〜１３のいずれかに記載の融合タンパク質。
- 創傷、異常な創傷治癒、瘢痕、または線維症の治療または予防において使用するための、請求項１〜１３のいずれかに記載の融合タンパク質。
- 請求項１〜１６のいずれかに記載の融合タンパク質をコードする核酸分子。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775252P | 2013-03-08 | 2013-03-08 | |
| US61/775,252 | 2013-03-08 | ||
| PCT/US2014/022052 WO2014138670A1 (en) | 2013-03-08 | 2014-03-07 | Ptd-smad7 therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510596A JP2016510596A (ja) | 2016-04-11 |
| JP2016510596A5 true JP2016510596A5 (ja) | 2017-03-30 |
| JP6576251B2 JP6576251B2 (ja) | 2019-09-18 |
Family
ID=51492023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561737A Active JP6576251B2 (ja) | 2013-03-08 | 2014-03-07 | ＰＴＤ−Ｓｍａｄ７薬物療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9422352B2 (ja) |
| EP (1) | EP2964774B1 (ja) |
| JP (1) | JP6576251B2 (ja) |
| CN (1) | CN105358704B (ja) |
| CA (1) | CA2904329C (ja) |
| HK (1) | HK1219986A1 (ja) |
| IL (1) | IL241190B (ja) |
| SG (1) | SG11201507045TA (ja) |
| WO (1) | WO2014138670A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3536337A1 (en) | 2010-09-22 | 2019-09-11 | The Regents of the University of Colorado, a body corporate | Therapeutic applications of smad7 |
| US9422352B2 (en) | 2013-03-08 | 2016-08-23 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
| KR101853923B1 (ko) * | 2016-01-25 | 2018-05-02 | 연세대학교 산학협력단 | Smad 단백질을 포함하는 자가 면역 질환 치료용 조성물, Smad 단백질을 포함하는 융합 단백질, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
| CN112004546A (zh) * | 2017-12-30 | 2020-11-27 | 科罗拉多大学董事会 | Ptd-smad7融合蛋白治疗剂 |
| WO2023044277A1 (en) * | 2021-09-15 | 2023-03-23 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 polypeptide formulations |
| WO2023150743A2 (en) * | 2022-02-07 | 2023-08-10 | Aavogen Inc. | Codon-optimized smad7 gene therapy to treat and prevent muscle wasting and to enhance muscle mass |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| JPH05505102A (ja) | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 真核細胞の中に分子を配達する方法 |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| CA2140910C (en) | 1992-07-27 | 1999-03-23 | Jeffrey A. Townsend | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| EP2000536A3 (en) | 1992-08-21 | 2010-06-30 | Biogen Idec MA, Inc. | Tat-derived transport polypeptides |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5436222A (en) | 1993-03-15 | 1995-07-25 | The Research Foundation Of State University Of New York | Use of platelet factor 4 to treat inflammatory diseases |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| GB2320431B (en) * | 1996-12-20 | 2000-08-30 | Johnson & Johnson Medical | Compositions for the treatment of chronic wounds |
| CA2290040A1 (en) | 1997-05-20 | 1998-11-26 | Ludwig Institute For Cancer Research | Smad7 and uses thereof |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| IL138692A0 (en) | 1998-03-27 | 2001-10-31 | Lilly Co Eli | Treatment and prevention of vascular disease |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6998240B2 (en) | 2001-06-11 | 2006-02-14 | Wisconsin Alumni Research Foundation | Screen for selective inhibitors or activators of Smad protein function |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| CA2496882C (en) | 2002-09-06 | 2011-11-01 | 3M Innovative Properties Company | Metering valve for a metered dose inhaler providing consistent delivery |
| KR100472938B1 (ko) | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
| NZ547105A (en) | 2003-10-16 | 2009-02-28 | Univ Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
| US8920782B2 (en) | 2005-01-14 | 2014-12-30 | Camurus Ab | Topical bioadhesive formulations |
| EP1866419A2 (en) | 2005-04-05 | 2007-12-19 | Pioneer-Hi-Bred International, Inc. | Methods and compositions for designing nucleic acid molecules for polypeptide expression in plants using plant virus codon-bias |
| CA2949643C (en) | 2005-09-27 | 2018-05-15 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| WO2008105925A2 (en) | 2006-09-01 | 2008-09-04 | Oregon Health & Science University | COMPOUNDS AND METHODS FOR MODULATING β-CATENIN/SMAD-7 INTERACTIONS |
| US20080114287A1 (en) | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
| CA2718904C (en) | 2008-03-17 | 2017-01-03 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US8591961B2 (en) | 2008-09-04 | 2013-11-26 | Allergan, Inc. | Aesthetic treatment of scars and aging skin |
| US20110152352A1 (en) | 2008-06-10 | 2011-06-23 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| EP3536337A1 (en) | 2010-09-22 | 2019-09-11 | The Regents of the University of Colorado, a body corporate | Therapeutic applications of smad7 |
| WO2013151667A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
| US9422352B2 (en) | 2013-03-08 | 2016-08-23 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
-
2014
- 2014-03-07 US US14/201,488 patent/US9422352B2/en active Active
- 2014-03-07 CA CA2904329A patent/CA2904329C/en active Active
- 2014-03-07 US US14/773,167 patent/US10456448B2/en active Active
- 2014-03-07 JP JP2015561737A patent/JP6576251B2/ja active Active
- 2014-03-07 EP EP14761076.0A patent/EP2964774B1/en active Active
- 2014-03-07 WO PCT/US2014/022052 patent/WO2014138670A1/en active Application Filing
- 2014-03-07 CN CN201480025596.9A patent/CN105358704B/zh active Active
- 2014-03-07 SG SG11201507045TA patent/SG11201507045TA/en unknown
-
2015
- 2015-09-06 IL IL241190A patent/IL241190B/en active IP Right Grant
-
2016
- 2016-06-23 HK HK16107300.2A patent/HK1219986A1/zh unknown
- 2016-07-12 US US15/208,424 patent/US20170000851A1/en not_active Abandoned
-
2019
- 2019-09-26 US US16/584,608 patent/US20200023037A1/en not_active Abandoned
-
2022
- 2022-04-22 US US17/727,579 patent/US20220370560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510596A5 (ja) | ||
| JP2012115277A5 (ja) | ||
| JP2013136622A5 (ja) | ||
| JP2012041342A5 (ja) | ||
| JP2018520646A5 (ja) | ||
| JP2017532343A5 (ja) | ||
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| JP2012102105A5 (ja) | ||
| JP2017518370A5 (ja) | ||
| BR112015008612A2 (pt) | métodos de tratamento utilizando adenovirus | |
| JP2014513952A5 (ja) | ||
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| JP2015514132A5 (ja) | ||
| BR112016027814A2 (pt) | sal de cloreto de tat-nr2b9c | |
| JP2017511133A5 (ja) | ||
| JP2013533273A5 (ja) | ||
| JP2014139185A5 (ja) | ||
| RU2016142580A (ru) | Новые способы, полипептиды и их применение | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| IN2014DN06920A (ja) | ||
| JP2014506231A5 (ja) | ||
| JP2018533970A5 (ja) | ||
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| JP2012521366A5 (ja) | ||
| JP2013507954A5 (ja) |